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Abstract
Background. Rotavirus is the leading cause of severe gastroenteritis in children worldwide. We evaluated 
the economic burden of rotavirus and the cost-effectiveness of vaccination from the health care perspective.
Methods. Estimates were based on existing epidemiological data, cost estimates, vaccine coverage, and 
efficacy data, as well as hypothetical vaccine prices. Outcome measures included health care and societal 
costs of rotavirus and benefits and incremental cost-effectiveness ratio of vaccination. Sensitivity analyses 
evaluated the impact of estimate uncertainty.
Results. Treatment costs increased with income level, and health burden decreased; however, burden varied 
across regions. On the basis of current vaccination coverage and timing, rotavirus vaccination would 
annually prevent 228,000 deaths, 13.7 million hospital visits, and 8.7 million disability-adjusted life-years, 
saving $188 million in treatment costs and $243 million in societal costs. At $5 per dose, the incremental 
cost-effectiveness ratio in low-, lower-middle–, and upper-middle–income countries was $88, $291, and 
$329 per disability-adjusted life-year averted, respectively, and $3,015, $9,951 and $11,296 per life saved, 
respectively. Vaccination would prevent 45% of deaths and 58% of associated medical visits and costs.
Conclusions. Vaccination is a cost-effective strategy to reduce the health and economic burden of rotavirus.
The cost-effectiveness of vaccination depends mostly on vaccine price and reaching children at highest risk 
ofmortality
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Rotavirus is the most common cause of severe gastro-
enteritis in young children worldwide and is estimated
to cause 1500,000 deaths, 12 million hospitalizations,
and 125 million clinic visits each year among children
!5 years of age [1]. In addition to the pain and suffering
in children, these rotavirus-associated events result in
increased medical expenses, lost productivity, and other
costs to society and families. Two effective rotavirus
vaccines have recently become available and could sig-
nificantly reduce this burden [2, 3].
Decisions to adopt vaccination programs depend on
multiple factors, including the health burden, vaccine
effectiveness, and cost-effectiveness of a vaccination
program. Although economic analyses have played a
central role in the consideration of new childhood vac-
cines for industrialized countries, decisions to introduce
new vaccines in developing countries have traditionally
been driven by data on disease burden. However, with
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Table 1. Input Variables and Ranges: General Parameters
Parameter Baseline estimate (range)
Distribution for
uncertainty analysis Reference(s)
Health
5-year risk of hospitalization for rotavirus infection
Low income 0.016 (0.012–0.02) Triangular [8]
Lower-middle income 0.020 (0.015–0.025) Triangular [8]
Upper-middle income 0.029 (0.022–0.036) Triangular [9–14]
5-year risk of an outpatient visit for rotavirus infection
Low income 0.202 (0.152–0.252) Triangular [8]
Lower-middle income 0.202 (0.152–0.252) Triangular [8]
Upper-middle income 0.233 (0.175–0.291) Triangular [8]
Hospital length of stay, days 4.0 (3–5) Triangular [9, 11, 14, 15–32]
Vaccine efficacy
Severe rotavirus GE resulting in hospitalization or death 0.85 (0.70–0.94) Log normal [33]
Moderate rotavirus GE resulting in outpatient visit 0.78 (0.58–0.89) Log normal [34, 33]
Effectiveness reduction with 1 dose 0.5 (0.25–0.75) Uniform Authors’ assumption
Effectiveness reduction in subsequent seasons for mild cases 0.04 (0–0.25) Uniform [35]
NOTE. Ranges for triangular and uniform distributions are minimum and maximum values, and ranges for log-normal distributions are 2.5th and 97.5th
percentiles. GE, gastroenteritis.
the increased availability of international resources to improve
childhood vaccination in developing countries, cost-effective-
ness analyses are increasingly used by policy-makers to allocate
resources among many competing priority interventions. Eco-
nomic evaluations of vaccines can assess whether they are cost
saving (averted costs are greater than the intervention) and
their cost-effectiveness (comparing net costs with the health
gains).
In the present study, we examined the economic burden of
rotavirus and the cost-effectiveness of vaccination in low- and
middle-income countries, which account for the vast majority
of the global burden of severe rotavirus gastroenteritis [1]. The
current analysis assessed the costs and effects of a rotavirus
vaccine, compared with current diarrheal control measures
without vaccination.
METHODS
Model overview. We analyzed the economic burden of ro-
tavirus and the cost-effectiveness of routine rotavirus vacci-
nation of infants in low- and middle-income countries. Coun-
tries were placed into the regional groups used by the World
Health Organization (WHO; African, American, eastern Med-
iterranean, European, Southeast Asian, and western Pacific
regions) [4], and each regional group was further divided into
3 income strata (low, lower middle, and upper middle) [5].
The regional income group was the unit of analysis, and a total
of 17 regional income groups were assessed. Countries included
in this analysis account for ∼99% of the global rotavirus mortality
burden [1] and 190% of the global 2004 birth cohort [6].
A Microsoft Excel–based model was developed to estimate
the health care and social costs of rotavirus gastroenteritis and
the cost-effectiveness of vaccination, which has been described
in detail elsewhere [7]. The model estimates health outcomes
(hospitalizations, outpatient visits, and deaths) of rotavirus dis-
ease and their associated costs for an annual birth cohort [6]
followed up for a 5-year period. It also estimates the disease
burden and health care costs averted as the result of vaccination.
The principal model inputs include epidemiological informa-
tion on disease incidence, health care treatment costs, and the
effectiveness and cost of vaccination (Tables 1 and 2).
The primary analysis was conducted from a health care sys-
tem perspective focusing on direct medical costs from hospi-
talization and outpatient visits. These include the cost of di-
agnostic tests, medication, supplies, facilities, and personnel.
Secondary analyses of economic burden were conducted from
a societal perspective and included transportation costs and
productivity losses of caregivers. No economic costs were in-
cluded for cases resulting in death or for patients not seeking
formal medical attention. The health burden of rotavirus was
also estimated in terms of disability-adjusted life-years (DALYs),
which quantify the years lost because of premature mortality
and the years lived with disability [38]. Loss of potential pro-
ductivity because of mortality was not included in the model.
The model also estimated the incremental cost-effectiveness
ratio (US$ per DALY averted and US$ per death averted) of
rotavirus vaccination. Estimates are expressed in 2007 US dol-
lars, and all future costs and DALY estimates are discounted at
a rate of 3%.
Rotavirus-associated hospitalizations, outpatient visits, and
mortality. For low-, lower-middle–, and upper-middle–in-
Table 2. Input Variables and Ranges: Region-Specific Parameters
Region, income group
Rotavirus-associated
mortality rate, deaths
per 1000 children !5
years of age
Hospital visit
treatment cost,
US$
Outpatient visit
treatment cost,
US$
Vaccine adminis-
tration cost,
US$
African
Low 2.17 43.84 4.10 0.48
Lower-middle 0.16 47.48 4.45 0.47
Upper-middle 0.27 71.18 6.75 0.94
Americas
Low 0.93 57.12 4.92 0.58
Lower-middle 0.27 113.23 10.79 0.67
Upper-middle 0.22 201.67 20.44 1.33
Eastern Mediterranean
Low 1.38 67.59 7.20 0.76
Lower-middle 0.38 88.43 8.99 0.73
Upper-middle 0.13 237.68 24.09 1.46
Europe
Low 0.73 71.52 6.35 1.30
Lower-middle 0.25 102.82 9.68 1.23
Upper-middle 0.001 174.55 19.52 2.46
Southeast Asia
Low 0.95 30.47 2.31 0.37
Lower-middle 0.26 58.27 5.02 0.25
Western Pacific
Low 0.69 55.82 4.56 0.27
Lower-middle 0.32 78.44 6.70 0.38
Upper-middle 0.06 103.78 9.12 0.77
NOTE. For the uncertainty analysis, a triangular distribution with bounds of 50% was used for cost parameters and of
10% for mortality. Data are from [8, 36, 37].
come countries, we estimated rates of rotavirus-associated hos-
pitalization and outpatient visits on the basis of the approach
described by Parashar et al [39]. Rotavirus-attributable hos-
pitalizations and outpatient visits were estimated by multiplying
the number of diarrhea-related hospitalizations and outpatient
visits by the estimated proportion of diarrhea events attrib-
utable to rotavirus [39]. Estimates of rates of hospitalization
and outpatient visits in upper-middle–income countries were
based on pooled results of studies conducted in 6 countries in
this income stratum [9–14]. The rate of outpatient visits was
estimated to be 8 times that of hospitalization [8]. Annual rates
were converted to 5-year cumulative rates.
Estimates of rotavirus mortality rate for each region-income
group were calculated on the basis of the population-weighted
mean of country-specific rates estimated by the WHO [1].
Rotavirus-associated hospitalizations and deaths were distrib-
uted into the following age categories based on a literature
review of the age distribution of rotavirus-associated hospital-
izations: 0–2 months, 3–5 months, 6–8 months, 9–11 months,
12–23 months, 24–35 months, 36–47 months, and 48–59
months [10, 11, 14, 40–65]. The distribution of outpatient visits
was assumed to be the same.
The DALY burden from rotavirus mortality was calculated
on the basis of the standardized life expectancy at 1 year of
age. The DALYs from cases of rotavirus disease resulting in
outpatient or hospital visits were calculated on the basis of
default disability weights [66] and an estimated illness duration
of 6 days [36]. To ensure comparability, DALY calculations
included age weights and a discount rate of 3% [67].
Economic costs associated with rotavirus. The direct med-
ical cost includes the costs of a visit or hospital stay and di-
agnostic tests and medications. Inpatient and outpatient visit
costs were estimated using standardized unit costs from the
WHO Choosing Interventions that are Cost Effective
(CHOICE) project, which estimates per diem hospitalization
costs and outpatient visit costs by geographical region and mor-
tality stratum [36]. The published function was used to estimate
country-specific hospital per diem costs for the present study.
The mean hospital and outpatient unit cost of each regional
income group was calculated by determining a population-
weighted mean of the country-specific cost estimates. The mean
length of hospital stay was estimated to be 4 days [9, 11, 14,
15–32]. Diagnostic and medication costs were estimated as a
proportion of the per diem and per visit costs from studies in
10 countries [68, 69]. Transportation cost and productivity
losses to care providers were estimated in the same manner.
Cost estimates were converted from 2000 international dollars
to 2007 US dollars with use of the Consumer Price Index [70],
purchasing power parity, and official exchange rates [71].
Vaccination: effectiveness and costs. The vaccine evaluated
was a live attenuated monovalent human rotavirus vaccine ad-
ministered orally with the first and second doses of diphtheria,
tetanus, and pertussis vaccine (DTP) at ∼2 and ∼4 months of
age, respectively [34]. To estimate vaccination effectiveness, the
model combined information on vaccine coverage, vaccine ef-
ficacy, and the relative coverage of children at high risk of
infection. Vaccine coverage was based on DTP coverage (doses
1 and 2) for each age category with use of 17 demographic and
health surveys conducted in low- and lower-middle–income
countries [72]. Demographic and health survey estimates were
similar to WHO–United Nations Children’s Fund (UNICEF)
best estimates for DTP coverage [37]. For the European region,
WHO-UNICEF estimates for DTP coverage were used because
of limited availability of DHS data, and it was assumed that
vaccination occurred at the recommended time. Because few
DHS data were available for upper-middle–income countries,
vaccine timing and coverage were assumed to be the same as
those in lower-middle–income countries.
Several studies suggest that infants who die of diarrhea are
less likely to have access to routine vaccinations [62, 73–75].
The model assumed that children who would die of diarrhea
in the absence of rotavirus vaccination have a lower level of
vaccination coverage. For the base case, vaccination coverage
among children at high risk of infection was assumed to be
90% (range, 50%–100%) that among children at low risk of
infection.
Vaccine efficacy against severe rotavirus disease resulting in
hospitalization was 85%, based on data from Latin America
[33]. This efficacy was also assumed for mortality. Efficacy
against outpatient visits was estimated as the mean efficacy
reported for severe (85%) [33] and any (70%) [34] rotavirus
gastroenteritis. The efficacy of receiving 1 dose was assumed
to be 50% of that of a full course.
The cost of vaccination includes administration costs, the
price of each dose, and expected losses from waste. Adminis-
tration costs for the low- and lower-middle–income countries
were estimated using the WHO Global Immunization Vision
and Strategy costing model [76]. Costs for the upper-middle–
income countries were assumed to be twice those for the lower-
middle–income group for each region. Because the current and
future price of rotavirus vaccines is currently unknown, the
analysis used a price range of $2–$15 per 2-dose course. A 10%
vaccine wastage rate was assumed. The cost of adverse events
associated with vaccination was not included, because the vac-
cine has a safety profile equivalent to that of placebo [34].
Cost-effectiveness. The primary measures of cost-effective-
ness in this study are the incremental cost per DALY averted
and incremental cost per death averted. The incremental cost
is the difference in the costs with and without vaccination (costs
of vaccination minus the averted costs from prevented cases).
The incremental cost-effectiveness ratio (ICER) is defined as
the incremental costs divided by the difference in the DALYs
(or deaths) with and without vaccination. Cost-effectiveness
was assessed from the health care system perspective for com-
parability with other published studies. The break-even price,
which is the price per vaccine dose at which the costs averted
because of vaccination exactly offset the costs of vaccination,
was calculated from the health care system and societal
perspective.
Uncertainty and sensitivity analyses. One-way sensitivity
analyses were completed by varying the individual values for
key model inputs among a high, low, and baseline estimate.
Variables included hospitalization, outpatient, and mortality
rates; vaccine efficacy; relative coverage; and vaccine coverage.
The model assumed that rotavirus vaccine coverage would be
the same as current coverage and timing for DTP doses 1 and
2. Scenario analyses were conducted to consider on-time cov-
erage, with children vaccinated at the recommended 2 and 4
months of age, and theoretical coverage, assuming both an
optimistic level of coverage based on WHO-UNICEF best es-
timates of coverage [37] and on-time vaccine delivery.
A probabilistic sensitivity analysis was conducted to develop
a range of estimates of burden and cost-effectiveness and to
identify specific variables that have substantial influence on
outcomes and that may merit additional data collection. A
Monte Carlo simulation model was developed using distribu-
tions for key input variables. Multiple iterations (10,000) gen-
erated output distributions and uncertainty limits (5% and
95%) for key variables [77]. Contribution to variance analysis
was conducted to determine which input variables contributed
the most to the uncertainty in the outputs. Variables used in
the model can be found in tables 1–3.
RESULTS
Health and economic burden. Annually, rotavirus accounts
for 527,025 deaths and 147 DALYs per 1000 children in all
countries included in this analysis (Table 3). Rotavirus-asso-
ciated outpatient visits and hospitalizations result in direct
medical treatment costs of $325 million ($202 million–$453
million) and total societal costs of $423 million ($262 million–
$590 million) each year. In general, there is an inverse rela-
tionship between the health burden and economic burden of
rotavirus, with health burden concentrated in low-income
countries and the economic burden concentrated in upper-
middle–income countries. There is also significant variation in
Table 3. Economic and Health Burden of Rotavirus Gastroenteritis by Region-Income Group (Cost per Annual Birth Cohort)
Region, income level
No. of medi-
cal visits
Medical cost Societal cost
No. of
deaths
DALYs per
1000
children1000 US$ US$ per child 1000 US$ US$ per child
Africa
Low 5,469,819 38,095 1.52 50,122 1.99 237,606 322
Lower-middle 408,373 3370 1.83 4386 2.38 1443 27
Upper-middle 30,636 426 3.64 548 4.68 141 41
All 5,908,828 41,891 1.55 55,056 2.03 239,190 300
Americas
Low 91,635 794 1.89 1042 2.47 1736 140
Lower-middle 780,851 15,501 4.40 20,192 5.73 4682 45
Upper-middle 1,995,810 80,980 10.62 104,493 13.71 8197 37
All 2,868,296 97,275 8.41 125,727 10.87 14,615 43
Eastern Mediterranean
Low 1,993,557 23,028 2.51 30,486 3.33 50,449 187
Lower-middle 1,275,197 20,420 3.55 26,683 4.64 10,111 60
Upper-middle 274,941 13,147 12.52 16,965 16.16 592 19
All 3,543,695 56,595 3.55 74,134 4.65 61,152 130
Europe
Low 328,233 3624 2.40 4756 3.15 5392 122
Lower-middle 818,298 14,658 3.97 19,081 5.17 4555 42
Upper-middle 185,127 6802 9.62 8820 12.48 4 0
All 1,331,658 25,084 4.25 32,657 5.53 9951 57
Southeast Asiaa
Low 7,876,061 34,172 0.94 44,501 1.23 161,253 152
Lower-middle 311,986 3034 2.16 3933 2.79 1732 42
All 8,188,047 37,206 0.99 48,434 1.29 162,985 148
Western Pacific
Low 558,083 4606 1.80 6021 2.35 8090 107
Lower-middle 4,596,693 59,937 2.89 77,653 3.74 30,890 51
Upper-middle 142,707 2802 5.14 3591 6.59 152 9
All 5,297,483 67,345 2.82 87,265 3.66 39,132 56
All regions
Low 16,317,388 104,322 1.39 136,929 1.83 464,526 211
Lower-middle 8,191,397 116,920 3.16 151,929 4.11 53,413 49
Upper-middle 2,629,222 104,157 10.37 134,417 13.39 9086 31
All 27,138,006 325,400 2.67 423,275 3.47 527,025 147
NOTE. DALYs, disability-adjusted life-years.
a No upper-middle–income countries were identified in the Southeast Asian region.
the health and economic burden among countries in different
geographic regions that fall into the same income category
Vaccine effectiveness and cost-effectiveness. With a na-
tional rotavirus vaccination program, an estimated 227,673 lives
(209,000–266,000 lives) would be saved in low- and middle-
income countries in each annual birth cohort (Table 4). In
addition to improving health, vaccination would save $188 mil-
lion ($121 million–$272 million) in treatment costs and $243
million ($157 million–$354 million) in total societal costs.
From the health care system perspective, vaccination would
be cost-saving in lower-middle– and upper-middle–income
regions for vaccine prices !$0.53 and !$2.00, respectively
(break-even price). Vaccination would require a net financial
investment at higher prices and at any price in the low-income
region. At a vaccine price of $5 per dose, the ICER was $88
($79–$126), $291 ($242–$402), and $329 ($173–$547) per
DALY averted in the low-, lower-middle–, and upper-middle–
income groups, respectively.
Table 5 shows the differences in benefits and cost-effective-
ness of vaccination among regions and income groups. In low-
income countries, vaccination would result in a smaller per-
centage reduction in rotavirus-associated deaths and medical
Table 4. Costs, Benefits, and Cost-Effectiveness of Rotavirus Vaccination by Income Group
Variable
Income group
Lower Lower-middle Upper-middle All
Total medical cost
Without vaccine 104,322,143 116,920,464 104,157,303 325,399,910
With vaccine 58,988,917 41,230,798 37,225,355 137,445,070
Averted 45,333,226 75,689,666 66,931,948 187,954,840
Percent reduction 0.43 0.65 0.64 0.58
Total societal costs averted 59,178,616 97,921,712 85,991,851 243,092,179
Cost of vaccination
$1/dose 162,294,905 109,857,673 46,436,100 318,588,677
$2/dose 275,851,447 182,831,561 66,912,285 525,595,293
$3/dose 389,407,989 255,805,449 87,388,470 732,601,908
$5/dose 616,521,073 401,753,224 128,340,841 1,146,615,138
$7.50/dose 900,412,428 584,187,944 179,531,305 1,664,131,676
Medical break-even price 0.03 0.53 2.00 0.37
Societal break-even price 0.09 0.84 2.93 0.64
DALYs
Without vaccine 15,827,898 1,827,512 311,876 17,967,286
With vaccine 9,372,297 706,807 125,357 10,204,462
DALYs averted 6,455,601 1,120,705 186,519 7,762,825
No. of deaths
Without vaccine 464,526 53,413 9086 527,025
With vaccine 275,057 20,645 3650 299,352
Averted 189,469 32,768 5436 227,673
Cost-effectiveness, US$ per DALY
$1/dose 18 30 Cost-saving 17
$2/dose 36 96 Cost-saving 43
$3/dose 53 161 110 70
$5/dose 88 291 329 123
$7.50/dose 132 454 604 190
Cost-effectiveness, US$/death
$1/dose 617 1043 Cost-saving 574
$2/dose 1217 3270 Cost-saving 1483
$3/dose 1816 5497 3763 2392
$5/dose 3015 9951 11,296 4211
$7.50/dose 4513 15,518 20,713 6484
NOTE. DALYs, disability-adjusted life-years.
visits, particularly in Africa and the eastern Mediterranean re-
gion (35%). The lower percentage reductions are attributable
to lower coverage rates and greater delays in vaccination in
these regions. Nevertheless, vaccination would be most cost-
effective in these same low-income countries because of the
higher overall rotavirus-associated mortality rates.
Sensitivity and uncertainty. Table 6 shows the results of
the 1-way sensitivity analysis for individual variables and their
contribution to variance in the probabilistic sensitivity analysis.
Results are shown for ICER at $5 per dose for each income
level. The contribution to variance shows the proportion of
overall uncertainty in cost-effectiveness attributable to the in-
dividual variable in the probabilistic model.
In low- and lower-middle–income regions, 3 variables con-
tribute the majority of uncertainty to the estimate of cost-
effectiveness: vaccine efficacy against rotavirus-associated
mortality, rotavirus-associated mortality rate, and relative vac-
cination coverage among children at the highest risk of rota-
virus-associated mortality, compared with children at lower
risk. In both income groups, vaccine efficacy contributes over
one-half of the overall uncertainty. In the low-income region,
economic variables have little effect on overall uncertainty. In
lower-middle– and upper-middle–income regions, economic
variables, including hospital and outpatient visit costs, con-
tribute more to overall uncertainty regarding cost-effectiveness.
Table 7 shows the estimated impact and cost-effectiveness of
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Table 6. Sensitivity and Uncertainty Analysis: Best and Worst Case Estimates of Cost-Effectiveness for Individual Variables (1-Way
Sensitivity Analysis) and Overall Contribution to Variance (Probabilistic Analysis)
Variable
Cost-effectiveness, US$/DALY at $5/dose
Low income Lower-middle income Upper-middle income
Worst Best
Contribution to
variance, % Worst Best
Contribution to
variance, % Worst Best
Contribution to
variance, %
Vaccine efficacy against mortality 122 82 65.9 386 261 55.7 449 305 12.4
Relative immunization coverage of
children at high risk of infection
103 88 16.7 326 279 13.6 380 325 2.8
Rotavirus-associated mortality rate 100 87 12.3 317 276 9.6 369 322 1.7
Vaccination program cost 96 91 1.7 305 285 2.0 389 299 6.3
Outpatient visit treatment cost 95 91 1.0 310 280 5.6 420 268 19.4
Hospital visit treatment cost 95 91 1.2 313 277 8.4 448 240 37.3
1-dose efficacy 94 92 !1 298 292 !1 351 337 !1
Vaccine efficacy for outpatient visits 94 92 !1 305 289 1.4 394 313 4.7
Vaccine efficacy for hospital visits 94 93 !1 303 290 !1 393 317 4.0
Outpatient visit rate 94 92 !1 300 290 !1 370 318 2.2
Hospital visit rate 94 93 !1 301 289 1.0 380 309 4.7
Length of hospital stay 94 93 !1 301 289 1.0 379 309 4.5
NOTE. Ranges and distribution of individual variables are shown in table 1.
vaccination for the 3 immunization scenarios examined: cur-
rent timing, on-time, and theoretical (on-time and increased
coverage). On-time immunization would increase the impact
of vaccination on mortality, particularly in low-income regions.
In the low-income countries in Africa, it would increase mor-
tality reduction by one-third and reduce the cost-effectiveness
ratio by 25%. The theoretical immunization scenario would
result in further increases in mortality reduction but no changes
in cost-effectiveness.
DISCUSSION
Rotavirus gastroenteritis annually results in 27 million hospital
and outpatient visits and 527,000 deaths among children !5
years of age in developing countries, at an estimated treatment
cost of $325 million and total societal costs of $423 million.
Assuming current vaccination coverage and timing, the inte-
gration of a rotavirus vaccine into national vaccination pro-
grams could prevent an estimated 227,000 deaths, 13.8 million
medical visits, and 7.8 million DALYs, saving $188 million in
treatment costs and $243 million in total costs. Vaccination
would not be cost-saving at most of the prices considered in
this analysis. However, the World Health Report (from 2002)
suggests that interventions are very cost-effective if the ICER
is less than the country’s per capita gross domestic product
and are cost-effective if the ICER is !3 times the per capita
gross domestic product [78]. With use of these standards, ro-
tavirus vaccination is very cost-effective in all income groups
for a range of vaccine prices evaluated in the analysis.
The value of rotavirus vaccination as a health investment
also depends on the other interventions available for improving
child health and the availability of financial resources. On the
basis of WHO-CHOICE, point-of-use water disinfection with
education is the most cost-effective water and sanitation in-
tervention in most regions, ranging from $161 per DALY in
countries in Africa with high mortality to $1092 per DALY in
countries in Latin America with low mortality. Introduction of
expanded oral rehydration therapy coverage to 50% as a part
of supplementation interventions had an ICER of !$25 per
DALY in Africa and 1$1200 per DALY in Latin America [79].
These comparisons suggest that rotavirus vaccination could be
as cost-effective as other interventions for prevention or treat-
ment of diarrhea, depending on vaccine price. However, dif-
ferences in the nature of these interventions and the lack of
empirical, directly compared cost-effectiveness trials limit the
comparability of these results.
Three factors that greatly affected the estimated performance
of a rotavirus vaccination program were the timing of vaccine
delivery, the overall vaccine coverage, and the relative vaccine
coverage among children who die of rotavirus, compared with
all children. If a rotavirus vaccine was delivered on time at the
age of 2 and 4 months and without the delays assumed in the
model, an additional 46,000 rotavirus deaths (total of 274,000
deaths) could be averted. Improving vaccination coverage to
the 90th percentile of coverage for each region and income
level and optimizing timing of vaccine delivery could prevent
an additional 125,978 deaths, compared with current vacci-
nation practices. In low-income countries, vaccination would
prevent 41% of rotavirus-related deaths with the current timing
and coverage, compared with 67% with optimal levels.
The sensitivity analyses identified several factors that are
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likely to influence the actual impact and cost-effectiveness of
vaccination. In low-income regions, the effectiveness of vac-
cination will be affected by the efficacy of vaccination in those
settings and the ability of vaccination to reach children at high
risk of infection on time. Several studies have identified a re-
lationship between immunization status and mortality, which
suggests that infants who have been vaccinated are less likely
to die than are infants who are not fully immunized [62, 73–75].
If those who die are less likely to have been vaccinated, the
effectiveness (and cost-effectiveness) of vaccination will be re-
duced. Targeted efforts to increase the coverage of children at
the greatest risk of mortality could improve the impact of vac-
cination programs.
Several limitations of this study should be considered in the
interpretation of the findings. First, estimates of health burden
and the impact of vaccination were based on a limited number
of publications that may not be generalizable to all countries
within income-region strata. Second, there are few empirical
data on resource use and cost for rotavirus gastroenteritis, par-
ticularly in developing countries. For this reason, a standardized
approach developed by the WHO for its WHO-CHOICE pro-
ject was used. Additional information on treatment and societal
costs may provide additional information on the economic
benefits of vaccination and potential cost offsets. Third, vaccine
price has a significant influence on the cost-effectiveness of
vaccination, but precise information on current and future costs
are not available. Additional analyses are needed to explore the
effect of likely prices on vaccine introduction and cost-effec-
tiveness. Finally, potential herd immunity of rotavirus vacci-
nation was not factored into our analysis; however, any herd
immunity effects of rotavirus vaccination would only improve
the overall cost-effectiveness of vaccination.
In conclusion, our findings indicate that vaccination can
effectively reduce the tremendous health and economic burden
of rotavirus gastroenteritis. Timing of vaccination, vaccination
coverage, and the ability of vaccination programs to reach chil-
dren at risk of death due to rotavirus disease will substantially
impact the effectiveness of vaccination. Although rotavirus vac-
cination is unlikely to be cost-saving from the health care per-
spective at the prices considered, vaccination is cost-effective
across a range of prices using several standards. Compared with
other interventions to reduce diarrhea-associated mortality, the
benefits of rotavirus vaccination may be achieved quickly be-
cause of the ability of the vaccine to be incorporated into ex-
isting immunization programs and the short time between vac-
cination and averted mortality. Although rotavirus vaccination
may be considered to be cost-effective, it will require an in-
vestment of resources to procure and deliver the vaccine, the
magnitude of which is determined by vaccine price. Although
some of these costs will be defrayed by averted medical costs,
additional national or international resources will likely be
needed to bring vaccines to children in the poorest countries
who need them the most. In the short term, external resources
may be available from international donors, such as funding
from the GAVI Alliance for eligible low-income countries; how-
ever, countries will need to identify internal resources for ro-
tavirus vaccination program sustainability.
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